PROSIEBENSAT1 MED. NPV (PBSFF) Given Neutral Rating at JPMorgan Chase & Co.
PROSIEBENSAT1 MED. NPV (OTCMKTS:PBSFF)‘s stock had its “neutral” rating reiterated by stock analysts at JPMorgan Chase & Co. in a research note issued on Friday.
Separately, DZ Bank AG reaffirmed a “sell” rating on shares of PROSIEBENSAT1 MED. NPV in a report on Friday, August 5th.
PROSIEBENSAT1 MED. NPV (OTCMKTS:PBSFF) traded up 3.77% during midday trading on Friday, hitting $42.16. 158 shares of the stock traded hands. The firm’s 50 day moving average is $44.35 and its 200-day moving average is $46.92. The stock has a market capitalization of $9.05 billion and a PE ratio of 22.17. PROSIEBENSAT1 MED. NPV has a 12-month low of $39.66 and a 12-month high of $53.96.
Receive News & Ratings for PROSIEBENSAT1 MED. NPV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. NPV and related companies with MarketBeat.com's FREE daily email newsletter.